Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial

References

• World Health Organization. Global strategy for dengue prevention and control: 2012–2020. Available from: http://www.who.int/denguecontrol/9789241504034/en/ (Accessed 7 July 2014) 2012
   Google Scholar
• National Vector Borne Disease Control Programme. Dengue cases and deaths in the country since 2008. Available at: http://nvbdcp.gov.in/den-cd.html (Accessed 7 July 2014) 2014
   Google Scholar
• Chakravarti A, Arora R, Luxemburger C. Fifty years of dengue in India. Trans R Soc Trop Med Hyg 2012; 106:273-82.; PMID:22357401; http://dx.doi.org/10.1016/j.trstmh.2011.12.007
   PubMed Web of Science ®Google Scholar
• Government of India. Guidelines for Clinical Management of Dengue Fever, Dengue Haemorrhagic Fever and Dengue Shock Syndrome. Available at: http://www.nvbdcp.gov.in/Doc/Clinical%20Guidelines.pdf (Accessed 7 July 2014) 2008
   Google Scholar
• Garg P, Nagpal J, Khairnar P, Seneviratne SL. Economic burden of dengue infections in India. Trans R Soc Trop Med Hyg 2008; 102:570-7; PMID:18402995; http://dx.doi.org/10.1016/j.trstmh.2008.02.015
   PubMed Web of Science ®Google Scholar
• Rai MA, Khan H. Dengue: Indian subcontinent in the line of fire. J Clin Virol 2007; 38:269-70; PMID:17254843; http://dx.doi.org/10.1016/j.jcv.2006.12.010
   PubMed Web of Science ®Google Scholar
• Kakkar M. Dengue fever is massively under-reported in India, hampering our response. BMJ 2012; 345:e8574; PMID:23255584; http://dx.doi.org/10.1136/bmj.e8574
   PubMedGoogle Scholar
• Shepard DS, Halasa YA, Tyagi BK, Adhish SV, Nandan D, Karthiga KS, Chellaswamy V, Gaba M, Arora NK, INCLEN Study Group. Economic and disease burden of dengue illness in india. Am J Trop Med Hyg 2014;91:1235-42; PMID:25294616; http://dx.doi.org/10.4269/ajtmh.14-0002
   PubMed Web of Science ®Google Scholar
• Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, et al. The global distribution and burden of dengue. Nature 2013; 496:504-7; PMID:23563266; http://dx.doi.org/10.1038/nature12060
   PubMed Web of Science ®Google Scholar
• Capeding RZ, Luna IA, Bomasang E, Lupisan S, Lang J, Forrat R, Wartel A, Crevat D. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine 2011; 29:3863-72; PMID:21477675; http://dx.doi.org/10.1016/j.vaccine.2011.03.057
   PubMed Web of Science ®Google Scholar
• Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012; 380:1559-67; PMID:22975340; http://dx.doi.org/10.1016/S0140-6736(12)61428-7
   PubMed Web of Science ®Google Scholar
• Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014; 384:1358-65; PMID:25018116; http://dx.doi.org/10.1016/S0140-6736(14)61060-6
   PubMed Web of Science ®Google Scholar
• Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, Deseda C, Reynales H, Costa MS, Morales-Ramirez JO, Carrasquilla G, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2015; 372:113-23; PMID:25365753; http://dx.doi.org/10.1056/NEJMoa1411037
   PubMed Web of Science ®Google Scholar
• Hss AS, Koh MT, Tan KK, Chan LG, Zhou L, Bouckenooghe A, Crevat D, Hutagalung Y. Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study. Vaccine 2013; 31:5814-21; PMID:24135573; http://dx.doi.org/10.1016/j.vaccine.2013.10.013
   PubMed Web of Science ®Google Scholar
• Tran NH, Luong CQ, Vu TQH, Lang J, Vu QD, Bouckenooghe A, Wartel TA. Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD- TDV) in healthy Vietnamese adults and children. J Vaccines Vaccin 2012; 3:162
   Google Scholar
• Leo YS, Wilder-Smith A, Archuleta S, Shek LP, Chong CY, Leong HN, Low CY, Oh ML, Bouckenooghe A, Wartel TA, et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore. Hum Vaccin Immunother 2012; 8:1259-71; PMID:22894958; http://dx.doi.org/10.4161/hv.21224
   PubMed Web of Science ®Google Scholar
• Anderson KB, Gibbons RV, Cummings DA, Nisalak A, Green S, Libraty DH, Jarman RG, Srikiatkhachorn A, Mammen MP, Darunee B, et al. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J Infect Dis 2014; 209:360-8; PMID:23964110; http://dx.doi.org/10.1093/infdis/jit436
   PubMed Web of Science ®Google Scholar
• Bhoomiboonchoo P, Nisalak A, Chansatiporn N, Yoon IK, Kalayanarooj S, Thipayamongkolgul M, Endy T, Rothman AL, Green S, Srikiatkhachorn A, et al. Sequential dengue virus infections detected in active and passive surveillance programs in Thailand, 1994-2010. BMC Public Health 2015; 15:250; PMID:25886528; http://dx.doi.org/10.1186/s12889-015-1590-z
   PubMed Web of Science ®Google Scholar
• Guzman MG, Kouri G, Valdes L, Bravo J, Vazquez S, Halstead SB. Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev Panam Salud Publica 2002; 11:223-7; PMID:12049030; http://dx.doi.org/10.1590/S1020-49892002000400003
   PubMedGoogle Scholar
• Halstead SB. Identifying protective dengue vaccines: guide to mastering an empirical process. Vaccine 2013; 31:4501-7; PMID:23896423; http://dx.doi.org/10.1016/j.vaccine.2013.06.079
   PubMed Web of Science ®Google Scholar
• Capeding MR, Laot TM, Boaz M, Wartel TA, Crevat D. Immunogenicity and safety of a tetravalent dengue vaccine during a five-year follow-up period. Trials in Vaccinology 2015; 4:19-23; http://dx.doi.org/10.1016/j.trivac.2015.03.002
   Google Scholar
• Qiao M, Shaw D, Forrat R, Wartel-Tram A, Lang J. Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans. Am J T rop Med Hyg 2011; 85:724-31; http://dx.doi.org/10.4269/ajtmh.2011.10-0436
   PubMed Web of Science ®Google Scholar
• Dayan GH, Garbes P, Noriega F, Izoton de Sadovsky AD, Rodrigues PM, Giuberti C, Dietze R. Immunogenicity and Safety of a Recombinant Tetravalent Dengue Vaccine in Children and Adolescents Ages 9-16 Years in Brazil. Am J Trop Med Hyg 2013; 89:1058-65; PMID:24189367; http://dx.doi.org/10.4269/ajtmh.13-0304
   PubMed Web of Science ®Google Scholar
• Torresi J, Heron LG, Qiao M, Marjason J, Chambonneau L, Bouckenooghe A, Boaz M, van der Vliet D, Wallace D, Hutagalung Y, Nissen MD, Richmond PC. Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study. 2015 Aug 13. pii: S0264-410X(15)01122-6; http://dx.doi.org/10.1016/j.vaccine.2015.08.008
   Google Scholar